top of page
Nuevocor_Assets_REV 3_2x.png

Therapeutic Pipeline
Pathway-Specific
Genetic Medicines

Nuevocor_R2-Revisions_edited_edited.jpg

Our Development Pipeline

PROGRAM

INDICATION

PHASE 1

PRECLINICAL

DISCOVERY

NVC-001A

LMNA DCM

NVC-002

UNDISCLOSED

ADDITIONAL

PROGRAMS

UNDISCLOSED

NVC-001B

UNDISCLOSED

Dilated Cardiomyopathy

LMNA Dilated Cardiomyopathy

Nuevocor’s lead program NVC-001 treat patients suffering lamin-related dilated cardiomyopathy by addressing the biomechanical root cause of disease. Dilated cardiomyopathy is a common cause of heart failure, characterized by enlargement of the left ventricle and a reduction in the ability of the heart to pump blood. Lamin-related dilated cardiomyopathy is among the top 3 most common causes of genetic dilated cardiomyopathy and has the worst prognosis of all dilated cardiomyopathies, making it a serious and aggressive disease. Today, other than receiving a cardiac transplant, there are no effective treatments available. 

Neuvocor Logo

Singapore

Nuevocor Pte. Ltd.

1 Biopolis Drive, Amnios #05-01
Singapore 138622

 

Email: info@nuevocor.com

United States

Nuevocor Therapeutics Inc.
500 Office Ctr Drive, Suite 400, 
Fort Washington, PA 19034

© 2024 Nuevocor. All rights reserved.

Follow Us

bottom of page